Sagimet Biosciences (SGMT) Common Equity (2023 - 2024)
Sagimet Biosciences (SGMT) has 2 years of Common Equity data on record, last reported at $170.7 million in Q3 2024.
- For Q3 2024, Common Equity rose 74.39% year-over-year to $170.7 million; the TTM value through Sep 2024 reached $170.7 million, up 74.39%, while the annual FY2023 figure was $91.1 million, N/A changed from the prior year.
- Common Equity reached $170.7 million in Q3 2024 per SGMT's latest filing, down from $183.3 million in the prior quarter.
- Across five years, Common Equity topped out at $190.0 million in Q1 2024 and bottomed at -$198.4 million in Q2 2023.